PortfoliosLab logoPortfoliosLab logo
CGTX vs. RXRX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CGTX vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cognition Therapeutics, Inc. (CGTX) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CGTX achieves a -19.26% return, which is significantly lower than RXRX's -12.96% return.


CGTX

1D
0.00%
1M
-9.92%
6M
-22.70%
YTD
-19.26%
1Y
92.10%
3Y*
-13.94%
5Y*
10Y*

RXRX

1D
-5.32%
1M
13.02%
6M
-23.61%
YTD
-12.96%
1Y
-32.58%
3Y*
-19.32%
5Y*
-38.40%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CGTX vs. RXRX - Yearly Performance Comparison


2026 (YTD)20252024202320222021
CGTX
Cognition Therapeutics, Inc.
-19.26%92.50%-62.09%-11.90%-66.77%-47.98%
RXRX
Recursion Pharmaceuticals, Inc.
-12.96%-39.50%-31.44%27.89%-54.99%-14.35%

Correlation

The correlation between CGTX and RXRX is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.31

Correlation (3Y)
Calculated over the trailing 3-year period

0.30

Correlation (All Time)
Calculated using the full available price history since Oct 8, 2021

0.23

Fundamentals

Market Cap

CGTX:

$80.20M

RXRX:

$1.59B

EPS

CGTX:

-$0.23

RXRX:

-$1.12

PB Ratio

CGTX:

3.25

RXRX:

1.84

Total Revenue (TTM)

CGTX:

$0.00

RXRX:

$66.29M

Gross Profit (TTM)

CGTX:

-$129.00K

RXRX:

-$22.83M

EBITDA (TTM)

CGTX:

-$23.57M

RXRX:

-$505.90M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CGTX vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CGTX
CGTX Risk / Return Rank: 6565
Overall Rank
CGTX Sharpe Ratio Rank: 6060
Sharpe Ratio Rank
CGTX Sortino Ratio Rank: 7272
Sortino Ratio Rank
CGTX Omega Ratio Rank: 7272
Omega Ratio Rank
CGTX Calmar Ratio Rank: 6161
Calmar Ratio Rank
CGTX Martin Ratio Rank: 5757
Martin Ratio Rank

RXRX
RXRX Risk / Return Rank: 2222
Overall Rank
RXRX Sharpe Ratio Rank: 2020
Sharpe Ratio Rank
RXRX Sortino Ratio Rank: 2222
Sortino Ratio Rank
RXRX Omega Ratio Rank: 2424
Omega Ratio Rank
RXRX Calmar Ratio Rank: 2121
Calmar Ratio Rank
RXRX Martin Ratio Rank: 2424
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CGTX vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cognition Therapeutics, Inc. (CGTX) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CGTXRXRXDifference
Sharpe ratioReturn per unit of total volatility

+0.96

Sortino ratioReturn per unit of downside risk

+2.07

Omega ratioGain probability vs. loss probability

1.21

0.95

+0.26

Calmar ratioReturn relative to maximum drawdown

0.69

-0.65

+1.34

Martin ratioReturn relative to average drawdown

1.04

-0.98

+2.03

CGTX vs. RXRX - Sharpe Ratio Comparison

The current CGTX Sharpe Ratio is 0.42, which is higher than the RXRX Sharpe Ratio of -0.54. The chart below compares the historical Sharpe Ratios of CGTX and RXRX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CGTX vs. RXRX - Drawdown Comparison

The maximum CGTX drawdown since its inception was -98.16%, which is greater than RXRX's maximum drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for CGTX and RXRX.


Loading charts...

Drawdown Indicators


CGTXRXRXDifference

Max Drawdown

Largest peak-to-trough decline

-98.16%

-93.13%

-5.03%

Max Drawdown (1Y)

Largest decline over 1 year

-81.30%

-58.17%

-23.13%

Max Drawdown (3Y)

Largest decline over 3 years

-90.88%

-82.09%

-8.79%

Max Drawdown (5Y)

Largest decline over 5 years

-92.11%

Current Drawdown

Current decline from peak

-91.60%

-91.39%

-0.21%

Average Drawdown

Average peak-to-trough decline

-84.36%

-75.60%

-8.76%

Ulcer Index

Depth and duration of drawdowns from previous peaks

53.71%

38.43%

+15.28%

Volatility

CGTX vs. RXRX - Volatility Comparison

Cognition Therapeutics, Inc. (CGTX) has a higher volatility of 55.80% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 15.85%. This indicates that CGTX's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CGTXRXRXDifference

Volatility (1M)

Calculated over the trailing 1-month period

55.80%

15.85%

+39.95%

Volatility (6M)

Calculated over the trailing 6-month period

89.67%

45.37%

+44.30%

Volatility (1Y)

Calculated over the trailing 1-year period

136.30%

70.10%

+66.20%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

119.82%

93.58%

+26.24%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

119.82%

93.21%

+26.61%

Dividends

CGTX vs. RXRX - Dividend Comparison

Neither CGTX nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CGTX vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between Cognition Therapeutics, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
6.47M
(CGTX) Total Revenue
(RXRX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


CGTX and RXRX have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CGTX has higher volatility (55.80%) compared to RXRX (15.85%). In terms of maximum drawdown, CGTX dropped -98.16% vs RXRX's -93.13%.

CGTX currently has the higher Sharpe Ratio (0.42 vs -0.54), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CGTX and RXRX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer